Target intelligence / Profile preview

Metabotropic glutamate receptor 1, 7, and 8 (mGluR1/7/8)

Target
mGluR1/7/8
Molecular classification
G protein-coupled receptor, Group I metabotropic glutamate receptor (mGluR1), Group III metabotropic glutamate receptor (mGluR7, mGluR8), Receptor
01

Overview

Metabotropic glutamate receptors 1, 7, and 8 (mGluR1, mGluR7, mGluR8) are G protein-coupled receptors that modulate excitatory neurotransmission in the central nervous system. mGluR1 belongs to Group I and is primarily postsynaptic, coupled to Gq proteins to increase intracellular calcium and promote neuronal excitability and synaptic plasticity. In contrast, mGluR7 and mGluR8 belong to Group III and are typically located presynaptically, where they couple to Gi/o proteins to inhibit adenylate cyclase and reduce the release of glutamate or other neurotransmitters. These receptors are critical for normal brain function, and their dysregulation is implicated in various neurological and psychiatric conditions, including schizophrenia, anxiety, and neurodegenerative disorders. Therapeutic strategies involve using allosteric modulators to fine-tune receptor activity, though achieving subtype selectivity remains a significant challenge in drug development.

Other names
mGlu1mGlu7mGlu8GRM1GRM7GRM8Metabotropic glutamate receptor 1Metabotropic glutamate receptor 7Metabotropic glutamate receptor 8
02

Mechanism of action

Drugs targeting these receptors act as orthosteric agonists/antagonists or positive/negative allosteric modulators (PAMs/NAMs) to either enhance or inhibit glutamatergic signaling and modulate synaptic excitability.

03

Biological functions

Signal transductionSynaptic plasticityNeurotransmission regulationExcitatory signaling (mGluR1)Presynaptic inhibition (mGluR7/8)Long-term potentiationLong-term depression
04

Disease associations

Neurodegenerative diseaseSchizophreniaAnxiety disorderEpilepsyChronic painAutism spectrum disorderAtaxia (mGluR1)Depression
05

Safety considerations

Motor impairment and ataxia (mGluR1 inhibition)Cognitive side effectsPro-convulsant or anti-convulsant risks depending on subtypePsychosis-like symptomsPotential for neurotoxicity with excessive activation
06

Interacting drugs

JNJ-16259685 (mGluR1 antagonist)

5 more in the full profile.

07

Biomarkers

Glutamate levels in cerebrospinal fluidPET imaging ligands (e.g., [11C]ABP688 for mGluR5, though less common for 1/7/8)mGluR1 autoantibodies (in paraneoplastic cerebellar degeneration)

Beyond the preview

Go deeper on Metabotropic glutamate receptor 1, 7, and 8 (mGluR1/7/8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabotropic glutamate receptor 1, 7, and 8 (mGluR1/7/8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call